A post hoc analysis of data from the GATHER1 and GATHER2 clinical trials showed that avacincaptad pegol achieved positive results in vision loss reduction in patients with geographic atrophy, according to a press release from Iveric Bio.
There was up to a 59% reduction in rate of vision loss with avacincaptad pegol (ACP) 2 mg compared with sham after 12 months of treatment.
GATHER1 had a 44% reduction in rate of vision loss, while GATHER2 had a 59% reduction. Together, the two clinical studies had a 56% reduction in rate (Read more...)